JPMorgan analyst Rohin Patel raised the firm’s price target on NeuroPace (NPCE) to $20 from $18 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
- NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
- NeuroPace announces Medicare reimbursement increases for RNS System
- NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- NeuroPace, Inc. Reports Record Revenue and Growth